Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
Rhea-AI Summary
Nektar (Nasdaq: NKTR) will announce fourth-quarter and year-ended December 31, 2025 financial results on Thursday, March 12, 2026 after U.S. market close. Howard Robin, president and CEO, will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT.
A live audio-only webcast and the press release will be available on the company’s Investors page. The webcast replay is available through April 12, 2026. Attendees must pre-register to receive dial-in details and a PIN for the live call.
Positive
- None.
Negative
- None.
News Market Reaction – NKTR
In the Feb 27 session, NKTR gained 4.67%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.4% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Conference participation | Positive | +2.9% | Announced participation in two March 2026 investor conferences with webcast access. |
| Feb 17 | Research collaboration | Positive | +3.5% | Collaboration with UCSF to study NKTR-0165 in multiple sclerosis models. |
| Feb 13 | Financing closed | Positive | +3.5% | Closed underwritten public offering raising about $460M via shares and pre-funded warrants. |
| Feb 11 | Upsized offering | Positive | +7.0% | Priced upsized $400M public offering to fund Phase 3 rezpegaldesleukin and other uses. |
| Feb 10 | Proposed offering | Positive | +18.5% | Proposed $300M offering under S-3ASR to fund R&D and Phase 3 trials. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including financings and collaborations, has generally coincided with positive price reactions.
Over the last few weeks, Nektar has issued several materially relevant updates. In early February, it announced a proposed offering, upsized it, and then closed a deal generating approximately $460 million, all tied to funding Phase 3 development of rezpegaldesleukin. Liquidity disclosures cited about $229.1 million in cash and marketable securities as of Jan 31, 2026. Additional news highlighted positive Phase 2b REZOLVE‑AD data and a multiple sclerosis collaboration around NKTR‑0165. These items, unlike today’s scheduling of an earnings date, tended to elicit positive price reactions.
Key Terms
earnings call financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through April 12, 2026.
To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco,
For Investors:
Vivian Wu
628-895-0661
VWu@nektar.com
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
For Media:
Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2025-on-thursday-march-12-2026-after-close-of-us-based-financial-markets-302698916.html
SOURCE Nektar Therapeutics